Taro News
Sun Pharma: Stellar show, robust outlook
Sun Pharma’s stock closed 2.76 per cent up on a stellar performance for the quarter and year ended March. Taro, its Israel-based subsidiary, clocked in a sales growth of 35 per cent year-on-year (y-o-y) at $145 million and continued driving growth in the quarter. US supplies of anti-cancer product, Lipidox, provided impetus, with US sales ($202 mn) growing 66 per cent y-o-y in the March quarter.
While
Taro Galleries
Taro Videos
|
|
